WIM
Woodford Investment Management Portfolio holdings
AUM
$310M
This Quarter Return
+8.11%
1 Year Return
-17.41%
3 Year Return
-27.69%
5 Year Return
+67.02%
10 Year Return
–
AUM
$2.42B
AUM Growth
+$2.42B
(+16%)
Cap. Flow
+$168M
Cap. Flow
% of AUM
6.95%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
8
New
1
Increased
5
Reduced
1
Closed
1
Top Buys
| 1 |
Gilead Sciences
GILD
|
$66.1M |
| 2 |
Prothena Corp
PRTA
|
$44.4M |
| 3 |
BIVV
Bioverativ Inc. Common Stock
BIVV
|
$43.1M |
| 4 |
Biogen
BIIB
|
$35.1M |
| 5 |
Theravance Biopharma
TBPH
|
$7.27M |
Top Sells
| 1 |
AbbVie
ABBV
|
$20.6M |
| 2 |
NWBO
Northwest Biotherapeutics, Inc. Common stock
NWBO
|
$8.64M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AbbVie
ABBV
$372B
| $711M | 29.45% | 10,917,258 -315,500 | -3% | -$20.6M |
|
|
2
Prothena Corp
PRTA
$441M
| $619M | 25.64% | 11,106,211 +795,700 | +8% | +$44.4M |
|
3
Alkermes
ALKS
$4.78B
| $437M | 18.09% | 7,470,528 +19,400 | +0.3% | +$1.13M |
|
|
4
Theravance Biopharma
TBPH
$699M
| $394M | 16.31% | 10,705,108 +197,500 | +2% | +$7.27M |
|
|
5
Gilead Sciences
GILD
$140B
| $108M | 4.47% | 1,588,100 +973,800 | +159% | +$66.1M |
|
|
6
Biogen
BIIB
$19.4B
| $103M | 4.26% | 376,788 +128,258 | +52% | +$35.1M |
|
|
BIVV
7
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $43.1M | 1.78% | +791,264 | New | +$43.1M |
|
|
NWBO
8
DELISTED
Northwest Biotherapeutics, Inc. Common stock
NWBO
| – | – | -24,815,028 | Closed | -$8.64M |
|